 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...3132333435363738394041...7475» |
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Comparing the efficacy of aflibercept and ranibizumab for the treatment of moderate to severe neovascular age related macular degeneration. (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1051;
This is largely consistent with current available literature however at present there are limited studies that have directly compared the efficacy of these two drugs over a treatment duration of longer than 1-2 years. There is therefore a need for further long term comparative data before any strong conclusions can be drawn.
- Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Brolucizumab in pre-treated neovascular AMD with high treatment demand: a case series (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1049;
These results are comparable to the improvement seen in a similar situation after switch from Ranibizumab to Aflibercept reported several years ago. While phase 3 HAWK and HARRIER studies showed non-inferiority with longer treatment intervals compared to aflibercept, our cases indicate an improved short-term treatment response one months after switch to Brolucizumab eyes with high treatment-demand.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Interest of observational period before treat and extend treatment (OTI) in exudative AMD: two years results (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1048;
After a loading dose of 3 injections of Aflibercept or Ranibizumab each patient was examinated (ETDRS Fundus examination OCT) each month during 6 month... We conclude that observational period, between loading dose and treat and extend treatment, permit sparing eyes from unnecessary injections during the first year of treatment with preservation of the visual acuity and retinal dryness.Personalization of every new patient with exudative AMD could be beneficial for every actor of this medical care including the patient on the first plan.We think this simplified treatment layout compared to treat&extend permit to obtain equivalent results in ‘real life’ with comfort and superior patients adherence partly thanks to the objective OCT relapse after induction and their understanding of the injection schedule.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] One year real-world outcomes of anti-VEGF therapy in neovascular age related macular degeneration (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1047;
We conclude that observational period, between loading dose and treat and extend treatment, permit sparing eyes from unnecessary injections during the first year of treatment with preservation of the visual acuity and retinal dryness.Personalization of every new patient with exudative AMD could be beneficial for every actor of this medical care including the patient on the first plan.We think this simplified treatment layout compared to treat&extend permit to obtain equivalent results in ‘real life’ with comfort and superior patients adherence partly thanks to the objective OCT relapse after induction and their understanding of the injection schedule. •Ranibizumab Treat and extend gaves the highest gain in vision for nAMD patients•Ranibizumab Treat and extend and Aflibercept treat and extend has the similar number of injections in the first year•Ranibizumab Prn protocol has low number of injections but also lower vision gain.•Ranibizumab Treat and extend and Aflibercept treat and extend protocols show similar number of active patients, while prn protocol patients are more active•All the protocols were great in central retinal thickness reduction, which is greatest in the Aflibercept group.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Subretinal fluid in neovascular age-related macular degeneration: to treat or not to treat (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1046;
The authors report a case that suggests that the presence of isolated SRF can be relatively well tolerated, even in the acute/sub-acute stages of nAMD, with minimal negative effects on vision. The importance of protocols is undoubted, but an individualized approach still have its place, bearing in mind possible side effects of therapy, risk/benefit ratio and patient’s preferences and expectations.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Effect of intravitreal ranibizumab on aortic stiffness in patients with age-related macular degeneration (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1045;
In particular, responders to the intravitreal injection of ranibizumab showed significant decrease in PWV and hsIL-6. Furthermore, exudative AMD was associated with increased aortic stiffness.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Assessing the visual function in mCNV patients after anti-VEGF treatment (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1041;
Furthermore, exudative AMD was associated with increased aortic stiffness. Integral lifting in several aspects of visual function, included visual acuity, metamorphopsia, average macular sensitivity, macular integrity and the fixation ability, was observed in mCNV patients after ranibizumab treatment.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] 24-month drug utilization patterns in neovascular age-related macular degeneration patients treated with licensed anti-vascular endothelial growth factor therapies in Canada: a real world study using the Ontario public claims database (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1040;
For both patient groups, more claims were made in months 0–12 compared to months 12–24. For the 30.8% of treatment-naïve patients who restarted therapy, half restarted within 150 days of discontinuing while among the 24.0% of treatment-experienced patients, 75% restarted within 188 days.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Bilateral simultaneous intravitreal injections in a tertiary hospital (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1037;
Bilateral simultaneous intravitreal injections present a low rate of complications and are well-tolerated by patients. This will reduce the burden on the health care system and on the patients.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Morphological biomarkers in retinal angiomatous proliferation and its correlation with visual acuity (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1035;
Final VA in RAP is strongly correlated with baseline and 3 months VA. The presence of fluid in the ONL may influence final prognosis.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Treatment adherence factors in patients receiving anti-VEGF therapy for macular neovascular diseases in real-life practice (preliminary report) (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1033;
The follow-up duration depends on the patient’s gender and age, the intensity of treatment, the initial and final BCVA, diagnosis (in particular, the duration of monitoring patients with mCNV is longer than with wAMD and DME). These findings reached a significance level of ˂ 0.05.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Anti-VEGF therapy of wet age-related macular degeneration: analysis of lost to follow-up patients in real clinical practice (preliminary report) (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1032;
The most common reasons for discontinuing anti-VEGF therapy (n = 83) were subjective dissatisfaction with IVT benefit, financial burden and general comorbidities, which were reported in 50 (60.2%), 27 (32.5%), 17 (20.5%) profiles respectively. Possible ways to increase patient's commitment to anti-VEGF therapy: early diagnosis and treatment initiation; selection of the most effective drugs and treatment regimens; individualization of treatment; organizational activities aimed at increasing the availability of specialized assistance.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Efficacy of switching a-vegf to aflibercept in wet amd treatment with ranibizumab resistance (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1031;
Switching A-VEGF therapy to IVI of aflibercept was accompanied by positive anatomical and functional dynamics and lengthening of the periods of relief of macular edema. To improve and prolong the anatomical and functional results of treating wet AMD, it is recommended that A-VEGF therapy be switched to aflibercept in resistance to ranibizumab after 15 IVI.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Interim analysis of health care parameters in Germany, the Netherlands and Switzerland related to neovascular AMD patients enrolled within the non-interventional PACIFIC study (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1030;
PACIFIC provides real-life data on nAMD management in patients treated with the anti-VEGF ranibizumab and on routine health care structural use in Germany, the Netherlands, and Switzerland. The value of observational insights from routine clinical practice in three different countries with a different health structure may lead to a better understanding of status quo and challenges in patient health care under real life settings and may therefore improve the quality and delivery of patient care.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Preoperative anti-vascular endothelial growth factor injections for tractional retinal detachments: bevacizumab versus ranibizumab (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_1013;
The value of observational insights from routine clinical practice in three different countries with a different health structure may lead to a better understanding of status quo and challenges in patient health care under real life settings and may therefore improve the quality and delivery of patient care. Preoperative bevacizumab(off-label) as an adjunct appears to be advantageous in reducing postoperative bleeding and aiding the complete removal of vitreous membranes in patients with macular involving diabetic tractional retinal detachments undergoing vitrectomy with membrane peeling, endolaser photocoagulation and silicone oil injection.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Scleral buckling surgery for active stage 4a and 4b retinopathy of prematurity (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_997;
Scleral buckling can be performed safely and effectively in 4a and 4b stage retinopathy of prematurity. This surgical technique may provide adequate relief of vitreoretinal traction with improved visual potential.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Three cases with coats disease stage 3A: same diagnosis, different course (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_921;
Due to the extent and severity of the findings, treatment modalities may differ in Coats disease. We emphasise the importance of individualized approach for anatomic and functional success.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Antiangiogenic therapy combined with OCT-navigated laser in the treatment of macular edema secondary to branch retinal vein occlusion (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_907;
The first clinical results obtained by us indicate sufficient efficacy and safety of combined antiangiogenic therapy with the OCT navigated laser treatment of macular edema secondary to BRVO and require further study. Due to the topographically oriented technology approach, it became possible to clearly localize and precisely influence on the pathological areas, with minimal damage to the adjacent structures.Using this technique, it’s possible to reduce the number of injections to achieve a required clinical result.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Prediction of ranibizumab injection frequency in patients with macular edema due to retinal vein occlusion during as-needed dosing period of BRAVO and CRUISE Phase 3 trials (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_902;
We show that the patients required variable injection frequency (0 to 6 injections) during the 6-month long PRN dosing period of the studies. BCVA at baseline and mean BCVA through the first 3 months of the initial monthly dosing period were associated with the greatest predictive signal of injection need.
- Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Distribution of retinal capillary non-perfusion on fluorescein angiogram corresponds to the anatomical absence of intermediate capillary plexus (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_895;
These findings suggest that if the retina is devoid of the ICP, it is more prone to ischaemia and although thinner can anatomically be perfused by the remaining superficial and deep capillary plexi. These observations should be confirmed by widefield OCT angiogram.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] DRIL influences short-term visual outcome after intravitreal corticosteroid injection for refractory diabetic macular edema (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_894;
Refractory DME managed with IVI of corticosteroid is associated with poor functional outcomes, despite a good anatomic response. Baseline BCVA and subfoveal DRIL on structural OCT are associated with better functional outcomes and should be considered when considering switching from IVI anti-VEGF to a corticosteroid agent.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Cost-consequence analysis of extended loading dose of anti-vegf treatment in diabetic macular edema patients (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_891;
The extension of anti-VEGF loading dose from 3 to 6 injections means that it would be necessary to invest €5,882.77 (8 injections), €10,091.03 (14 injections) and €10,198.59 (30 injections) per additional patient (3-month non-responder and 6-month responder) responding to aflibercept, ranibizumab and bevacizumab, respectively. For the total of patients treated, on average €7,927.02 per additional responder patient would be needed.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] When is the appropriate time to switch to steroid implant in recalcitrant Diabetic Macular Edema not responding to anti-VEGF (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_887;
Switching to steroid implant after 4-6 anti VEGF injections showed the best functional results when compared to other groups in our study. Rise in Intra ocular pressure was not a serious issue in our study groups.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Drug utilization in patients treated with anti-VEGFs for diabetic macular edema (DME) in the UK (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_884;
Our data shown an average number of injections during the first year of treatment that was numerically higher (7.7) compared to those reported in the POLARIS (7.4) and Moorfields Eye Hospital (6.7).Overall >59%, >27% of treated eyes had treatment free intervals ≥q12-, ≥q16-weeks during the first and second years after treatment initiation. However, in many of the cases extension by >12 weeks occurred only once (during the entire two-year period).Our results highlight the need for therapeutic solutions that enable sustainable extended injection intervals while controlling anatomical parameters and improving and maintaining long-term vision.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Can early functional response to anti-vascular endothelial growth factor (VEGF) therapy for macular oedema associated with retinal vein occlusion predict longer term visual outcome? (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_876;
Counselling patients regarding visual loss at M12 based on response to treatment at M1 or M3 is unreliable. When considering offering alternative therapies to patients, waiting for M3 visual outcome data may offer an advantage over M1 data.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Treatment of macular edema secondary to central retinal vein occlusion. Results in "Real Life" at 24 months. (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_872;
These results seem to be inferior when compared with RCT reference data. This difference might be explained by fewer follow-ups in Real-Life than in RCT protocols.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Under pressure – a cohort analysis of sustained-elevation intraocular pressure in long-term VEGF inhibitor therapy (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_871;
Regardless of the indication, regular intravitreal anti-VEGF injections (?of Bevacizumab, Ranibizumab or Aflibercept) do not appear to be associated with an increased risk of SEIOP post-injection. A previous history of glaucoma is the greatest risk factor for SEIOP in these patients.The intraocular pressure of patients with a history of glaucoma should be monitored carefully, including when being treated with intravitreal Anti-VEGFs.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] 24-month outcomes of intravitreal aflibercept in the United Kingdom for diabetic macular oedema (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_867;
Fourty-nine (62.8%) and five (6.4%) eyes were previously treated with intravitreal ranibizumab and intravitreal dexamethasone implants respectively and had stopped responding to treatment... Intravitreal aflibercept is a safe treatment for DMO, significantly improving vision in a real-world cohort with significant ocular co-morbidities that had responded poorly to other treatments.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Intravitreal injections for macular edema secondary to retinal vein occlusion: long-term functional and anatomic outcomes (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_866;
A safety profile similar to that already well-established in Ranibizumab and Dexamethasone treatment was observed, as well as a steady decrease in the number of intraocular injections required. The results support intravitreal treatments for BRVO and CRVO in patient populations with similar characteristics in similar settings.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Treat and extend versus relaxed pro re nata regimens of ranibizumab in diabetic macular edema: a two-year real-world matched comparison study (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_851;
The results support intravitreal treatments for BRVO and CRVO in patient populations with similar characteristics in similar settings. The T&E regimen of ranibizumab resulted in better visual improvement and less fluctuation of CRT than the relaxed PRN regimen in treating DME.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Spectral-domain optical coherence tomography parameters predicting long-term functional and morphological outcomes in patients with diabetic macular edema following a treat and extend regimen under ranibizumab (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_840;
An intact IS/OS junction at baseline seems to be a predictor for a dry retina in patients with DME being treated with ranibizumab following a TER. Other OCT features like HRT and the height of the biggest cyst seem not to have predicting power.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Should we use intravitreal dexamethzone implant as an adjuvan therapy or switch therapy in refractory diabetic macula edema (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_833;
Purpose: To compare the outcomes of intravitreal dexamethasone implant used as an adjuvant therapy or a switching therapy in diabetic macula edema in the event of anatomical poor response after 3 consecutive monthly ranibizumab. In a real-world setting, eyes with DME considered refractory to ranibizumab therapy after three monthly injections which were switched to IDI implant and had better visual and anatomical outcomes at 12 months than those that continued treatment with ranibizumab therapy after IDI as an adjuvan therapy.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] A comparative study of treatments for macular oedema secondary to branch retinal vein occlusion in 5,661 people (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_815;
The outcomes help inform both clinician and patient choice. Although it shows that patients fall short of visual acuity outcomes compared with key randomised clinical trials, anti-VEGF treatment outperforms steroid implants and both outperform macular laser.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Association between fluctuations in central retinal thickness and visual acuity following treatment with anti-VEGF therapy in diabetic macular edema (DME) in the UK (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_814;
Findings were consistent with published evidence. EURETINA guidelines stated a modest (-0.41 to -0.31) correlation during the first year of treatment with anti-VEGFs, that weakens in the long term.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Central multifocal choroiditis: an evaluation of different treatment options in pregnancy. (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_792;
Overall, no major complications were observed in patients treated with immunosuppressive medication or intravitreal anti-VEGF injections. Although more relapses occurred in pregnancies without immunosuppressive treatment, we emphasize no definite conclusions can be drawn based on this small retrospective study.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Optical coherence tomography angiography cyclic remodeling of CNV in patients affected by BEST macular dystrophy (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_765;
OCT-A is an important tool for the diagnosis of both naïve and fibrotic CNV in BMD patients; it is a non-invasive method for the qualitative and quantitative analysis of neovascular lesion during the follow-up. Our results demonstrated a cyclic remodeling of treated CNV in BMD patients using both PDT and intravitreal injections.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Functional and structural outcomes of temporal zone II-sparing laser photocoagulation combined with intravitreal lucentis (ranibizumab) in retinopathy of prematurity from 2016 till 2019 in KSA (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_728;
Our results demonstrated a cyclic remodeling of treated CNV in BMD patients using both PDT and intravitreal injections. Temporal Zone II-sparing laser treatment combined with Lucentis (ranibizumab) showed good early treatment outcome and temporal retinal vessels development
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Involution of retinopathy of prematurity and neurodevelopmental outcomes after Intravitreal Lucentis (ranibizumab) treatment (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_704;
Purpose: This single-centered, retrospective cohort study investigated the timing of involution of retinopathy of prematurity (ROP) and retinal vascularization to zone III after intravitreal bevacizumab (IVB) treatment and its possible impacts on postnatal growth and neurodevelopment Setting: KASER ALINE FACULTY OF MEDICIN CAIRO UNEVISTY CAIRO EGYPT Premature infants with birth weight ‰¤1500 g, born between 2008 to 2014 and diagnosed with ROP were enrolled. : Long-term follow-up showed no significant differences in body weight and neurodevelopment between the study and control groups up to the 2-year corrected age
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Ranibizumab non-response in pachychoroid neovasculopathy: effects of switching to aflibercept (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_644;
: Long-term follow-up showed no significant differences in body weight and neurodevelopment between the study and control groups up to the 2-year corrected age In cases of PNV not responding to intravitreal ranibizumab, switching treatment to aflibercept seems to represent an effective treatment approach to resolve persistent fluid and achieve a dry macula.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Optical coherence tomography angiography findings after intravitreal ranibizumab in patients with coats disease (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_613;
This preliminary study shows that intravitreal anti-VEGF injections could not be useful in treating of Coats disease, because the increased levels of VEGF are not involved in its pathogenesis. OCTA is a non-invasive vascular imaging modality that could support the diagnosis and follow up of these patients.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Analysis of optical coherence tomography angiographic findings of premature children: its relationship with macular edema of prematurity (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_590;
Whole vascular density is decreased in preterm children and more prominent in superficial layers. MEOP does not seem to have an effect on retinal microvascular development, but associated with outer retinal thickness in preterm children.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Pars plana vitrectomy for endophthalmitis after intravitreal treatment in exudative AMD: the unexpected long-term results. (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_541;
All antivegf agents were related to IE (aflibercept being the most related). A consultant was the most frequent injector.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Association between retinal fluid and change in visual acuity in 23,646 eyes treated for neovascular age-related macular degeneration with intravitreal aflibercept or ranibizumab (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_539;
Our findings support results from clinical trials that report the toleration of low levels of SRF does not have a negative impact on visual outcomes. A major limitation of the study is that the recording of fluid as an indication for retreatment is highly variable across sites.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Evolving paradigms in the treatment of neovascular AMD: are we getting better? Outcomes of a treatment cohort of 13,297 eyes with up to 10-year follow-up (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_528;
The data reflects this by showing a reducing number of visits per unit time, with a similar to slightly increasing number of injections in the same time interval, suggesting a shift to more TREX approaches over the last decade. Improvement over time of both final VA and baseline VA supports the fact that we are improving the outcomes of our patients with these more cost-effective treatment strategies.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] A retrospective, real-world evidence study of patients with age-related macular degeneration (AMD) to evaluate the economic burden in Spain: RAMDEBURS project (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_523;
From the Spanish hospital perspective, in terms of direct healthcare costs, AMD results in a huge economic burden. Diagnostics tests and procedures costs are the most important factor in the burden of the disease.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Long-term outcomes of intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration: a real-world evidence study. (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_518;
91% of eyes still needed treatment in the last examination. Switch between different drugs and combined PDT was necessary in 55% and 36% percent of eyes respectively.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Real-world anti-VEGF treatment patterns and healthcare resource utilisation for neovascular age-related macular degeneration in Japan: a retrospective cohort study (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_517;
Evaluation of real-world treatment patterns for patients with nAMD in Japan showed that the majority of patients had ≥2 ophthalmologist visits without an injection between visits with injections, possibly reflecting pro re nata treatment. Less than half of all patients received loading doses, and the mean number of anti-VEGF injections during the first year of treatment was lower than in clinical trials, indicating that real-world treatment patterns deviate from recommended regimens.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Healthcare resource utilization and cost for nAMD patients treated with anti-vascular endothelial growth factors in Canada based on the anatomical and functional outcomes: The FOCUS study (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_515;
Irrespective of anti-VEGF treatment, most patients visit their ophthalmologists for the loss of visual function. As periodic assessment of disease progression is necessary in nAMD, patients would undergo at the minimum diagnostic tests such as OCT and/or FA assessments.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Exploration of real world outcomes and treatment patterns in patients treated with anti-VEGFs for neovascular age-related macular degeneration (nAMD) in Sweden (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_503;
VA gain was higher after three years in index period 2014-2015 despite baseline VA being higher in this index period. At three years, around one fifth of the eyes were treated at long intervals.
- Lucentis (ranibizumab) / Roche, Novartis, Rayoqta (abicipar pegol) / Molecular Partners, AbbVie
[VIRTUAL] Abicipar for nAMD Provides Faster Retinal Fluid Resolution and Achieved Similar Dryness through Week 104 with Fewer Injections (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_498;
Abicipar Q8 and Q12 showed faster initial clearance of subretinal, intraretinal, and any fluid compared to rQ4 group. The percent of patients with dry retinas at Week 104 were similar for each arm with fewer injections for abicipar Q8 (14 injections) and Q12 (10 injections) vs ranibizumab Q4 (25 injections).